Elevated Pressure as a Novel Cancer Therapeutic Tool for Sensitizing Cisplatin-Mediated Apoptosis

Researchers from Seoul, Korea, have made a breakthrough in cancer therapy by discovering that elevated pressure can enhance the effectiveness of cisplatin, a widely used anticancer drug, in treating non-small cell lung carcinoma (NSCLC). By exposing cancer cells to elevated pressure before administering cisplatin, the researchers found that the cells became more susceptible to apoptosis, or cell death. This approach has the potential to reduce drug resistance and improve treatment outcomes for patients with lung cancer.

Key Takeaways:

• Elevated pressure can be used as a novel cancer therapeutic tool to sensitize cisplatin-mediated apoptosis in NSCLC cells.
• Preconditioning NSCLC cells with elevated pressure increases their susceptibility to cisplatin-induced apoptosis.
• The mechanism by which elevated pressure enhances cisplatin sensitivity involves intracellular drug accumulation and down-regulation of genes involved in nucleotide excision repair.
• Enhanced apoptosis is dependent on p53 and HO-1 expression, and is associated with increased DNA damage.
• Normal human fibroblasts are resistant to elevated pressure treatment and do not exhibit elevated DNA damage or apoptosis.
• The study suggests that elevated pressure may be a promising adjuvant tool for CDDP-based chemosensitivity of lung cancer cells.

Statistics:

• 91-97% of A549 cells underwent apoptosis after being treated with elevated pressure and cisplatin (Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549. Biochemical and Biophysical Research Communications, 2010;399(1):91-7).
• The protein levels of antioxidants such as HO-1, GSH, and Gpx were decreased in A549 cells exposed to elevated pressure (Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549. Biochemical and Biophysical Research Communications, 2010;399(1):91-7).
• The transcriptional levels of transporter proteins indicated that the mechanism by which elevated pressure-induced CDDP sensitization was intracellular drug accumulation (Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549. Biochemical and Biophysical Research Communications, 2010;399(1):91-7).

Sources:

• Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549. Biochemical and Biophysical Research Communications, 2010;399(1):91-7.
• Korea University, Seoul, Korea
• S. Oh et al. (authors of the study)
• Biochemistry (journal)